These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23953051)

  • 41. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
    Derosa G; Mugellini A; Pesce RM; D'Angelo A; Maffioli P
    BMC Cardiovasc Disord; 2016 Apr; 16():66. PubMed ID: 27068332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Iwasaka T
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Pharmacology of Manidipine for the Treatment of Hypertension: Importance of Renal and Additional Organ Protective Properties. Proceedings of a symposium. Madrid, Spain, June 13, 1992.
    Am Heart J; 1993 Feb; 125(2 Pt 2):559-648. PubMed ID: 8094264
    [No Abstract]   [Full Text] [Related]  

  • 44. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
    Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal protection with calcium antagonists: the role of lercanidipine.
    Burnier M
    Curr Med Res Opin; 2013 Dec; 29(12):1727-35. PubMed ID: 24069902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats.
    Lee JJ; Shin CY; Park HJ; Zhang WY; Kim Y; Kim IS; Lee KH; Myung CS
    Arch Pharm Res; 2010 Sep; 33(9):1411-8. PubMed ID: 20945140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Derivatives of 1,4-dihydropyridines as "priviledged structures" and their pharmacological potential].
    Żorniak M; Mitręga K; Krzemiński TF
    Kardiol Pol; 2011; 69 Suppl 3():100-3. PubMed ID: 22125212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lercanidipine-induced chylous ascites: Case report and literature review.
    Basualdo JE; Rosado IA; Morales MI; Fernández-Ros N; Huerta A; Alegre F; Landecho MF; Lucena JF
    J Clin Pharm Ther; 2017 Oct; 42(5):638-641. PubMed ID: 28485829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses.
    van Zwieten PA; Pfaffendorf M
    J Hypertens Suppl; 1993 Dec; 11(6):S3-8. PubMed ID: 8169379
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.
    Takahara A
    Cardiovasc Ther; 2009; 27(2):124-39. PubMed ID: 19426250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats.
    Rosenthal T; Rosenmann E; Tomassoni D; Amenta F
    J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):145-52. PubMed ID: 17562785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lercanidipine in worldwide usage.
    Zanchetti A
    Curr Med Res Opin; 2015 Jan; 31(1):161-2. PubMed ID: 25425127
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical advantages of lipophilic dihydropyridines.
    Mancia G; Omboni S; Zanchetti A
    Blood Press Suppl; 1998; 2():23-6. PubMed ID: 9850439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
    Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G
    Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice.
    Cicero AF; Gerocarni B; Rosticci M; Borghi C
    Clin Exp Hypertens; 2012; 34(2):113-7. PubMed ID: 21967031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calcium channel blockers in cardiovascular pharmacotherapy.
    Godfraind T
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):501-15. PubMed ID: 24872348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue.
    Brixius K; Gross T; Tossios P; Geissler HJ; Mehlhorn U; Schwinger RH; Hekmat K
    Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):708-13. PubMed ID: 16173926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
    Iskenderov BG; Burmistrova LF; Berenshteĭn NV; Lokhina TV
    Kardiologiia; 2007; 47(11):44-5. PubMed ID: 18260963
    [No Abstract]   [Full Text] [Related]  

  • 59. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved?
    Corsini A; Accomazzo MR; Canavesi M; Sartani A; Testa R; Catapano AL; Fumagalli R; Paoletti R; Bernini F
    Blood Press Suppl; 1998; 2():18-22. PubMed ID: 9850438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
    Striessnig J; Ortner NJ; Pinggera A
    Curr Mol Pharmacol; 2015; 8(2):110-22. PubMed ID: 25966690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.